The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma. Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel. Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer. The TITAN-TCC trial examined the safety and efficacy of nivolumab induction with ipilimumab as an immunotherapeutic boost. A team of researchers set out to determine the preferred sequence of perioperative systemic therapy for node-positive UTUC. Rachelle Rodriguez, MS, APRN, AOCNP, highlights her role in helping Moffitt grow its APP presence within the GU onc program. IFNα and nadofaragene firadenovec can provide a new therapy approach for a disease with a significant unmet clinical need. BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC. Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC. Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium. Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC. Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC. Daniel P. Petrylak, MD, overviews the TROPHY-U-01 study for platinum-ineligible patients with metastatic UC. Christine Ibilibor, MD, shares the race disparities in UC diagnoses and outcomes, as well as strategies to mitigate them. Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC. A study presented at the 2023 ASCO GU Cancers Symposium evaluated K17 expression in several forms of urothelial carcinoma. A research team sought to define the tumor protein co-expression of PD-L1, c-MET, and HER2 in a cohort of patients with mUC. IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy. Researchers analyzed the impact of EV+P or EV alone on QOL and symptoms based on the EV-103 Cohort K trial. A recent study analyzed the effectiveness of BCG treatment in patients with NMIBC, including a subgroup of patients with CIS.